KKM Financial LLC Boosts Stake in Solventum Co. (NYSE:SOLV)

KKM Financial LLC boosted its position in shares of Solventum Co. (NYSE:SOLV) by 7.9% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,367 shares of the company’s stock after buying an additional 319 shares during the period. KKM Financial LLC’s holdings in Solventum were worth $304,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Cerity Partners LLC increased its stake in Solventum by 27.4% during the third quarter. Cerity Partners LLC now owns 52,719 shares of the company’s stock worth $3,676,000 after acquiring an additional 11,337 shares during the last quarter. Biltmore Family Office LLC purchased a new position in shares of Solventum in the 3rd quarter worth approximately $236,000. Banco Santander S.A. bought a new position in shares of Solventum during the 3rd quarter valued at approximately $215,000. Thompson Siegel & Walmsley LLC purchased a new stake in Solventum during the 3rd quarter valued at $7,719,000. Finally, Cypress Capital Group lifted its position in Solventum by 9.1% in the third quarter. Cypress Capital Group now owns 20,706 shares of the company’s stock worth $1,444,000 after buying an additional 1,719 shares during the last quarter.

Analysts Set New Price Targets

SOLV has been the topic of several recent analyst reports. Morgan Stanley increased their target price on shares of Solventum from $60.00 to $73.00 and gave the company an “equal weight” rating in a research note on Monday, November 11th. Wolfe Research started coverage on shares of Solventum in a research report on Thursday, September 26th. They issued a “peer perform” rating on the stock. Wells Fargo & Company dropped their target price on Solventum from $69.00 to $64.00 and set an “equal weight” rating for the company in a research report on Friday, August 9th. The Goldman Sachs Group increased their price target on Solventum from $48.00 to $54.00 and gave the stock a “sell” rating in a report on Monday, August 12th. Finally, Piper Sandler boosted their price objective on Solventum from $71.00 to $75.00 and gave the company a “neutral” rating in a report on Friday, November 8th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and one has issued a buy rating to the stock. According to MarketBeat, Solventum has an average rating of “Hold” and a consensus price target of $68.00.

Solventum Trading Up 1.7 %

Shares of NYSE SOLV opened at $70.81 on Friday. The stock has a 50 day moving average price of $70.53 and a 200 day moving average price of $62.35. Solventum Co. has a 52-week low of $47.16 and a 52-week high of $96.05. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 2.45.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.